MX9401191A - Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. - Google Patents

Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Info

Publication number
MX9401191A
MX9401191A MX9401191A MX9401191A MX9401191A MX 9401191 A MX9401191 A MX 9401191A MX 9401191 A MX9401191 A MX 9401191A MX 9401191 A MX9401191 A MX 9401191A MX 9401191 A MX9401191 A MX 9401191A
Authority
MX
Mexico
Prior art keywords
preparation
pharmaceutical compositions
sulfamoil
procedure
contain
Prior art date
Application number
MX9401191A
Other languages
English (en)
Inventor
Claudine Serrradeil-Le
Gerard Valette
Bernard Crhistophe
Loic Foulon
Alain Pellet
Original Assignee
Sanofi Elf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Elf filed Critical Sanofi Elf
Publication of MX9401191A publication Critical patent/MX9401191A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención se refiere a nuevos compuestos comprendiendo simultáneamente en particular un grupo sulfamoilo sustituido y un grupo amidino, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. Estos compuestos tienen en particular una cierta afinidad por los receptores biológicos del neuropéptido Y, NPY, presentes en los sistemas nervioso central y periférico.
MX9401191A 1993-02-15 1994-02-15 Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. MX9401191A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9301686A FR2701480B1 (fr) 1993-02-15 1993-02-15 Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
MX9401191A true MX9401191A (es) 1994-08-31

Family

ID=9444071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9401191A MX9401191A (es) 1993-02-15 1994-02-15 Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Country Status (23)

Country Link
US (2) US5506258A (es)
EP (1) EP0614911B1 (es)
JP (1) JP2994546B2 (es)
KR (1) KR940019682A (es)
CN (1) CN1104634A (es)
AT (1) ATE179430T1 (es)
AU (1) AU673398B2 (es)
CA (1) CA2115631A1 (es)
DE (1) DE69418083T2 (es)
DK (1) DK0614911T3 (es)
ES (1) ES2132351T3 (es)
FI (1) FI940680A (es)
FR (1) FR2701480B1 (es)
GR (1) GR3030243T3 (es)
HU (1) HUT66960A (es)
IL (1) IL108649A (es)
MX (1) MX9401191A (es)
NO (1) NO304313B1 (es)
NZ (1) NZ250878A (es)
PH (1) PH30887A (es)
RU (1) RU2126382C1 (es)
TW (1) TW372233B (es)
ZA (1) ZA941029B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5668151A (en) * 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
DK0861236T4 (da) * 1995-11-13 2006-12-18 Sanofi Aventis Deutschland Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
WO1997020822A1 (en) * 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
US6433185B1 (en) 1996-01-11 2002-08-13 Sanofi-Synthelabo N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
AU2042897A (en) * 1996-03-21 1997-10-10 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives
DK0984778T3 (da) 1996-08-23 2002-09-16 Agouron Pharma Neuropeptid-Y-ligander
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
AU6144098A (en) * 1997-02-14 1998-09-08 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US5889016A (en) * 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
CO5011105A1 (es) * 1997-12-22 2001-02-28 Novartis Ag Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion
GB2344050A (en) * 1998-11-26 2000-05-31 Ferring Bv Agents useful in the treatment of reproductive disorders.
FR2819254B1 (fr) * 2001-01-08 2003-04-18 Fournier Lab Sa Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
AU2002314744A1 (en) * 2001-04-17 2002-10-28 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
FR2840897B1 (fr) 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
JP4593559B2 (ja) * 2003-03-25 2010-12-08 ラボラトワール フルニエ エス・アー ベンゼンスルホンアミド誘導体、その製造方法、及び、痛みを治療するためのその使用
DE602004026289D1 (de) 2003-05-05 2010-05-12 Probiodrug Ag Glutaminylcyclase-hemmer
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
AU2005210004B2 (en) 2004-02-05 2010-10-28 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
MX2009011615A (es) * 2007-06-05 2009-11-10 Sanofi Aventis Acidos benzoilamino-indan-2-carboxilicos sustituidos y compuestos relacionados.
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
FR2949674A1 (fr) * 2009-09-10 2011-03-11 Oreal Utilisation d'un antagoniste du neuropeptide y pour augmenter le volume et/ou la coloration naturelle des levres
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
US11813268B2 (en) 2017-10-17 2023-11-14 Albert Einstein College Of Medicine Mitofusin activators and uses thereof
EP3740466B1 (en) 2018-01-17 2024-03-06 Migal Galilee Research Institute Ltd. New methionine metabolic pathway inhibitors
EP3740482A1 (en) 2018-01-17 2020-11-25 Migal Galilee Research Institute Ltd. New methionine metabolic pathway inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT84171B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados das n alfa-aril-sulfonilamiminoacil-p- -amidinofenil-alaninamidas, bem como dos seus derivados de sintese e das composicoes farmaceuticas que os contem
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
DE3939797A1 (de) * 1989-12-01 1991-06-06 Basf Ag Neue vom neuropeptid y abgeleitete peptide
WO1992016549A1 (de) * 1991-03-18 1992-10-01 Pentapharm Ag Para-substituierte phenylalanin-derivate
JP3283114B2 (ja) * 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤

Also Published As

Publication number Publication date
IL108649A0 (en) 1994-05-30
DK0614911T3 (da) 1999-11-08
FR2701480A1 (fr) 1994-08-19
KR940019682A (ko) 1994-09-14
HUT66960A (en) 1995-01-30
DE69418083T2 (de) 1999-11-25
NO940503L (es) 1994-08-16
JP2994546B2 (ja) 1999-12-27
TW372233B (en) 1999-10-21
NO940503D0 (no) 1994-02-14
EP0614911A1 (fr) 1994-09-14
EP0614911B1 (fr) 1999-04-28
CA2115631A1 (en) 1994-08-16
DE69418083D1 (de) 1999-06-02
NZ250878A (en) 1996-02-27
GR3030243T3 (en) 1999-08-31
RU2126382C1 (ru) 1999-02-20
US5674890A (en) 1997-10-07
ATE179430T1 (de) 1999-05-15
ES2132351T3 (es) 1999-08-16
FI940680A0 (fi) 1994-02-14
AU5516594A (en) 1994-08-18
HU9400414D0 (en) 1994-05-30
ZA941029B (en) 1995-08-15
JPH06293794A (ja) 1994-10-21
PH30887A (en) 1997-12-23
NO304313B1 (no) 1998-11-30
CN1104634A (zh) 1995-07-05
FI940680A (fi) 1994-08-16
US5506258A (en) 1996-04-09
FR2701480B1 (fr) 1995-05-24
IL108649A (en) 1998-09-24
AU673398B2 (en) 1996-11-07

Similar Documents

Publication Publication Date Title
MX9401191A (es) Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
ATE9695T1 (de) Antihistamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
MX9202025A (es) Nuevos compuestos di alquilen piperidino y su enantiomeros, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
MX9204354A (es) Compuestos heterociclicos de 5 miembros, procedimiento para prepararlos y composiciones farmaceuticas que los contienen.
FI973279A (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
ES2190479T3 (es) Moduladores de rxr selectivos a dimeros y metodos para su uso.
MX9203972A (es) Compuestos inhibidores de la proteasa codificada por el virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulado farmaceutico que los contiene.
ES2018478B3 (es) Un sistema para preparar una composicion desensibilizante dental.
AR008991A1 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina, procedimientos para su preparacion y aplicacion de los mismos
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
MX9201295A (es) Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contienen.
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
ES2187738T3 (es) Derivados de flavonas, su procedimiento de preparacion y los compuestos farmaceuticos que las contienen.
MX9201642A (es) Derivados de amidino fenil alanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
MX9204031A (es) Sal de l-ascorbato de 16-descarboxi-16-hidroximetil-amfotericina b, proceso para su preparacion y composicion farmaceutica que contiene dicha sal.
PT1057826E (pt) Derivados carboxamidicos dimericos substituidos processo para a sua preparacao e as composicoes farmaceuticas que os contem
MX9202300A (es) Derivados de benzofurano, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9303572A (es) Inhibidores de proteasa del sindrome de inmunodeficiencia humana, procedimiento para su preparacion y formualcion farmaceutica que los contiene.
BR9705456A (pt) Compostos heterocìclicos, processo de aminometila para sua preparação e composições farmacêuticas que os contêm.
PT90661A (pt) Processo para a preparacao de composicoes farmaceuticas contendo inibidores da enzima conversora de angiotensina e moduladores de canal de potassio
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
MX9207269A (es) Bencimidazoles substituidos, proceso para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: NORTH CAROLINA STATE UNIVERSITY

PD Change of proprietorship

Owner name: SANOFI-SYNTHELABO

MM Annulment or lapse due to non-payment of fees